Safety and Efficacy of Combined Peptide Receptor Radionuclide Therapy and Liver Selective Internal Radiation Therapy in a Patient With Metastatic Neuroendocrine Tumor

Research output: Contribution to journalArticle

Abstract

Nuclear medicine treatments of well-differentiated neuroendocrine tumors (NETs) are gaining increasing acceptance among clinicians. Peptide receptor radionuclide therapy (PRRT) is an effective systemic treatment, providing a significant survival benefit and improving patients' quality of life. Locoregional selective internal radiation therapy (SIRT) is a safe and effective treatment for unresectable NET liver metastases, providing good local tumor control and symptomatic relief. Few reports in literature examine the sequential use of PRRT and SIRT in metastatic NET. We report the case of a metastatic NET patient treated with sequential PRRT-SIRT achieving a long disease control interval without cumulative toxicity issues.

Original languageEnglish
Pages (from-to)e286-e288
JournalClinical Nuclear Medicine
Volume44
Issue number4
DOIs
Publication statusPublished - Apr 1 2019

    Fingerprint

Keywords

  • liver metastases
  • neuroendocrine tumors
  • peptide receptor radionuclide therapy
  • radionuclide therapy
  • selective internal radiation therapy
  • transarterial radioembolization

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this